The ten important active constituents were chosen for molecular docking verification with the key targets TNF, AKT1, EGFR, and GSK3β (the core intersection target of the PPI network and Component-pathway-target network, Figure 9a), which are considered potential targets in the treatment of diabetes. This evidence concerns the gene AKT1 and diabetes mellitus.